Document is current
Any future updates will be listed below
-
Authors
Koplev, Simon https://orcid.org/0000-0002-8586-5614
Seldin, Marcus
Sukhavasi, Katyayani https://orcid.org/0000-0001-5627-0163
Ermel, Raili
Pang, Shichao
Zeng, Lingyao
Bankier, Sean https://orcid.org/0000-0001-5069-3165
Di Narzo, Antonio
Cheng, Haoxiang https://orcid.org/0000-0002-1393-6006
Meda, Vamsidhar
Ma, Angela
Talukdar, Husain
Cohain, Ariella
Amadori, Letizia https://orcid.org/0000-0003-1125-4631
Argmann, Carmen https://orcid.org/0000-0002-1110-8012
Houten, Sander M. https://orcid.org/0000-0002-6167-9147
Franzén, Oscar
Mocci, Giuseppe
Meelu, Omar A. https://orcid.org/0000-0002-3481-2731
Ishikawa, Kiyotake
Whatling, Carl
Jain, Anamika
Jain, Rajeev Kumar
Gan, Li-Ming
Giannarelli, Chiara https://orcid.org/0000-0003-2473-6058
Roussos, Panos https://orcid.org/0000-0002-4640-6239
Hao, Ke https://orcid.org/0000-0002-1815-9197
Schunkert, Heribert https://orcid.org/0000-0001-6428-3001
Michoel, Tom https://orcid.org/0000-0003-4749-4725
Ruusalepp, Arno
Schadt, Eric E. https://orcid.org/0000-0002-7892-8808
Kovacic, Jason C. https://orcid.org/0000-0003-4555-769X
Lusis, Aldon J. https://orcid.org/0000-0001-9013-0228
Björkegren, Johan L. M. https://orcid.org/0000-0003-1945-7425
-
Funding
Funding for this research was provided by:
Fondation Leducq (12CVD02, 12CVD02, 12CVD02, 12CVD02, 12CVD02)
Bundesministerium für Gesundheit (01ZX1706C, 16GW0198K, ZF4590201BA8)
Department of Industry, New South Wales | NSW Department of Primary Industries (RG194194)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL125863)
American Heart Association (A14SFRN20840000)
Vetenskapsrådet (2018-02529, 2020-02529_3)
Independent research support by AstraZeneca to the Karolinska Institutet, the Integrated CardioMetabolic Center
- License Information
-
More Information
Article History
Received: 4 May 2021
Accepted: 27 November 2021
First Online: 12 January 2022
Competing interests
: J.L.M.B. is the founder of Clinical Gene Networks (CGN). J.L.M.B. (chair) and A.R. are on CGN’s board of directors. J.L.M.B., A.R. and T.M. are shareholders in CGN. J.L.M.B. receives financial compensation as a consultant for CGN. CGN has an invested interest in STARNET that is regulated in an agreement with the Icahn School of Medicine at Mount Sinai. Neither the Icahn School of Medicine at Mount Sinai nor CGN have made claims to results presented in this study. E.E.S. is the CEO of Sema4. C.W. and L.-M.G. are employees of AstraZeneca. No funding for this study was received from Sema4. AstraZeneca supported this study through independent grants to J.L.M.B. at the Karolinska Institutet (ICMC). The remaining authors declare no competing interests.
